Polypyridyl Zinc(II)-Indomethacin Complexes with Potent Anti-Breast Cancer Stem Cell Activity
AbstractCancer stem cells (CSCs) are thought of as a clinically pertinent subpopulation of tumors, partly responsible for cancer relapse and metastasis. Research programs aimed at discovering anti-CSC agents have largely focused on biologics and purely organic molecules. Recently, we showed that a family of redox-active copper(II) complexes with phenanthroline-based ligands and nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin, are capable of potently and selectively killing breast CSCs. Herein we present analogous redox-inactive, zinc(II)-phenanthroline-indomethacin complexes with the ability to kill breast CSCs and bulk breast cancer cells with equal potency (in the submicro- or micromolar range). A single dose of the zinc(II) complexes could theoretically be administered to eliminate whole tumor populations. Excitingly, some of the zinc(II) complexes decrease the growth and viability of mammospheres to a comparable or higher degree than salinomycin, a compound known to effectively kill breast CSCs. As far as we are aware this is the first report to examine the anti-breast CSC activity of zinc(II)-containing compounds. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 481 KB)
Share & Cite This Article
Rundstadler, T.K.; Eskandari, A.; Norman, S.M.; Suntharalingam, K. Polypyridyl Zinc(II)-Indomethacin Complexes with Potent Anti-Breast Cancer Stem Cell Activity. Molecules 2018, 23, 2253.
Rundstadler TK, Eskandari A, Norman SM, Suntharalingam K. Polypyridyl Zinc(II)-Indomethacin Complexes with Potent Anti-Breast Cancer Stem Cell Activity. Molecules. 2018; 23(9):2253.Chicago/Turabian Style
Rundstadler, Tiffany K.; Eskandari, Arvin; Norman, Sarah M.; Suntharalingam, Kogularamanan. 2018. "Polypyridyl Zinc(II)-Indomethacin Complexes with Potent Anti-Breast Cancer Stem Cell Activity." Molecules 23, no. 9: 2253.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.